Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy

This study tests a combination of three treatments — adebrelimab (an immune checkpoint inhibitor), famitinib (a drug that cuts off the blood supply to tumors), and irinotecan (chemotherapy) — for people with advanced stomach or gastroesophageal junction cancer that has stopped responding to standard first-line treatment. **You may be eligible if...** - You have a confirmed diagnosis of advanced gastric (stomach) or gastroesophageal junction adenocarcinoma - Your cancer has progressed or stopped responding to first-line treatment (including chemotherapy and an immune checkpoint inhibitor used for at least 3 months) - You have at least one measurable tumor lesion that has not received local radiation - Your overall health and organ function meet the required criteria **You may NOT be eligible if...** - You have not yet tried first-line systemic treatment - Your cancer has not failed first-line therapy - Your physical condition or organ function does not meet minimum requirements Talk to your doctor to see if this trial is right for you.